Hi, today we are going to talk about Precision BioSciences and its current landscape.
Precision BioSciences, the genome editing company has received attention lately as the Cancer - Drug Race heats up, in the middle a day of the announcements of a $5.2 billion total in Acquisitions by big names of the pharmaceuticals sector, such as Merck & Co. and Sanofi, that...
Precision Biosciences is a cancer and genetic therapeutic company,
based in North Carolina that went public this past March at 18.00 a share.
The "3 Box Technical Indicator" shown here, shows DTIL
has made a Very Powerful " V Bottom Breakout" this past week.
When you purchase a stock,always look for "over performance",as a key criteria to ownership.
When a stock gets this much Analysts attention in the one day we take notice. With the average price target of $24 this has huge upside potential. It is a name that requires much more research but we are very interested by these upgrades.